RxDoctor Payments Data

Scott Ainsworth, MD

Gastroenterology · Blairsville, GANPI 1033196183

Payments from drug & device makers

$744in general payments, 2019–2025

Across 33 payments — averaging $22.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$222
  • Takeda Pharmaceuticals U.S.A., Inc.$218
  • Melinta Therapeutics, LLC$124
  • AbbVie$66
  • Nestle Healthcare Nutrition Inc.$38
  • Boston Scientific$17
  • plus $58 from 4 others

What the payments were for

  • Food & beverage$744100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$744 in reported general payments places this provider in the 20th percentile of 492 gastroenterology providers in Georgia.

See all gastroenterology providers in Georgia

Medicare billing

Part B allowed, 2024
$166,373
Medicare patients
699
Services billed
1,256

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase11$17,751
LinzessLinaclotide33$17,286
Colestipol Hcl97$13,383
Lansoprazole15$2,883
Omeprazole318$1,925
Budesonide EcBudesonide24$1,625
Balsalazide Disodium12$1,586
Mercaptopurine13$1,316
Budesonide DrBudesonide23$1,074
Dicyclomine Hcl62$990
Cholestyramine LightCholestyramine17$974
Azathioprine16$960
Pantoprazole Sodium79$667
Famotidine82$534
Esomeprazole Magnesium16$145

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$66$35,03744 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 492 gastroenterology providers in Georgia.

Other gastroenterology in Blairsville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →